Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis

Simple item page
dc.authoridNas, Kemal/0000-0002-5845-0851
dc.authoridKavuncu, Vural/0000-0003-2619-4977
dc.authoridAkyuz, Gulseren/0000-0002-3724-571X
dc.authoridAKARIRMAK, ZEYNEP ULKU/0000-0002-3288-3368
dc.authorwosidAKARIRMAK, ZEYNEP ÜLKÜ/AAA-3923-2020
dc.authorwosidNas, Kemal/HSG-2378-2023
dc.authorwosidKavuncu, Vural/AAF-7251-2020
dc.authorwosidAkyuz, Gulseren/H-9819-2019
dc.contributor.authorAki, S
dc.contributor.authorEskiyurt, N
dc.contributor.authorAkarirmak, Ü
dc.contributor.authorTüzün, F
dc.contributor.authorEryavuz, M
dc.contributor.authorAlper, S
dc.contributor.authorArpacioglu, O
dc.date.accessioned2024-06-12T11:11:46Z
dc.date.available2024-06-12T11:11:46Z
dc.date.issued2003
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe aim of our study was to evaluate the upper gastrointestinal (GI) tract side effect profile in 759 female patients that had taken alendronate (10 mg/day), for at least 6 months, for the treatment of osteoporosis, in relation to the safety of alendronate and the compliance of patients to its absorption rules. This study was a multicentered retrospective, clinical, non-placebo controlled, study of 759 female subjects carried out at 26 centres in 6 different regions of Turkey. The mean age of our patients was 62.6 +/- 8.6, with 51.2% in the age range 60 to 69 years. 158 patients (20.8%) were considered to have upper GI tract complaints with nausea as the most often encountered symptom. Of the subjects with upper GI tract complaints, 20% reported discontinued drug use, and 30% reported the requirement of an additional drug in order to abolish their complaints. Approximately 537 (71%) of the patients stated they had been given written information about the administration of the drug, and at least 93 patients (12%) and 73 patients (18.4%) acknowledged non compliance with the safety and absorption rules, respectively. In our study, no significant difference was found between the adherence to the safety measures and upper GI tract complaints (p>0.05), but that upper GI tract complaints were higher in patients taking additional medication to alendronate (p<0.05).en_US
dc.identifier.doi10.3349/ymj.2003.44.6.961
dc.identifier.endpage967en_US
dc.identifier.issn0513-5796
dc.identifier.issn1976-2437
dc.identifier.issue6en_US
dc.identifier.pmid14703602en_US
dc.identifier.scopus2-s2.0-9144227463en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage961en_US
dc.identifier.urihttps://doi.org/10.3349/ymj.2003.44.6.961
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22923
dc.identifier.volume44en_US
dc.identifier.wosWOS:000187959500003en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherYonsei Univ Coll Medicineen_US
dc.relation.ispartofYonsei Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectOsteoporosisen_US
dc.subjectAlendronateen_US
dc.subjectGastrointestinal Systemen_US
dc.subjectSide Effect Profileen_US
dc.subjectFracture-Intervention-Trialen_US
dc.subjectBone Massen_US
dc.subjectPostmenopausal Womenen_US
dc.subjectVertebral Fracturesen_US
dc.subjectRandomized-Trialen_US
dc.subjectOral Alendronateen_US
dc.subjectDensityen_US
dc.subjectRisken_US
dc.subjectMechanismsen_US
dc.subjectSymptomsen_US
dc.titleGastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosisen_US
dc.typeArticleen_US

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize